Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer
作者: Debra L. RichardsonFloor J. BackesLeigh G. SeamonVanna ZanagnoloDavid M. O'MalleyDavid E. CohnJeffrey M. FowlerLarry J. Copeland
作者单位: 1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA
刊名: Gynecologic Oncology, 2008, Vol.111 (3), pp.461-466
来源数据库: Elsevier Journal
DOI: 10.1016/j.ygyno.2008.08.011
关键词: GemcitabineBevacizumabPlatinumRecurrent epithelial ovarian cancerBevacizumabBowel perforation
原始语种摘要: Abstract(#br)Objective(#br)To describe the response rate (RR), progression-free survival (PFS), and toxicity profile of combination gemcitabine, platinum, and bevacizumab (GPB) for the treatment of recurrent epithelial ovarian cancer (EOC).(#br)Methods(#br)A chart review of all patients with recurrent EOC who were treated with D1, D15 GPB in a 28-day cycle at a single institution was performed. Standard doses were gemcitabine 1000 mg/m 2 , cisplatin 30 mg/m 2 or carboplatin AUC 3, and bevacizumab 10 mg/kg. All patients were analyzed for toxicity. RR and PFS were assessed in all patients who received at least 2 cycles of GPB.(#br)Results(#br)Thirty-five patients were identified, and 33 received at least 2 cycles of GPB. The majority of patients (80%) were platinum sensitive. Patients...
全文获取路径: Elsevier  (合作)
影响因子:3.929 (2012)

  • platinum 
  • ovarian 卵巢的
  • recurrent 循环的
  • treatment 处理
  • epithelial 上皮的
  • neutropenia 中性白细胞增多
  • combination 聚形
  • survival 生存
  • toxicity 毒性
  • serious 认真的